Product image of Melfalano Teva (Melphalan Hydrochloride) supplied by GNH India

Melfalano Teva

Active Ingredient:
Melphalan Hydrochloride
Origin:
EU

Melfalano Teva (Melphalan Hydrochloride)

Melphalan Hydrochloride, the active ingredient in Melfalano Teva, is an alkylating agent presented as an injectable solution for intravenous systemic use. It is employed in the treatment of various malignancies, including multiple myeloma, ovarian cancer, melanoma, neuroblastoma, and other solid tumors, by targeting rapidly dividing cancer cells.

GNH India supplies Melfalano Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use.

Manufacturer / TM Owner

Teva B.V

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Melfalano Teva (melphalan hydrochloride) is used in chemotherapy regimens for several solid tumor and hematologic malignancies.

  • Multiple myeloma: incorporated into conditioning or combination protocols to achieve disease control.
  • Ovarian cancer: administered as part of multi‑agent chemotherapy to reduce tumor burden.
  • Melanoma: used in high‑dose regimens for metastatic disease management.
  • Neuroblastoma: employed in intensive therapy schedules for pediatric patients.
  • Other solid tumors: applied in various combination regimens where alkylating activity is required.

How It Works

  • Melphalan hydrochloride acts as an alkylating agent that forms covalent cross‑links between DNA strands. By binding to the N7 position of guanine bases, it creates inter‑ and intra‑strand bonds that impede DNA replication and transcription, ultimately triggering apoptosis in rapidly proliferating cancer cells.

Side Effects

Melfalano Teva may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset commonly reported during treatment.
  • Myelosuppression: reduced white blood cells, red blood cells, and platelets.
  • Fatigue: persistent tiredness affecting daily activities.
  • Mucositis: inflammation of the mouth and gastrointestinal lining.
  • Alopecia: hair loss that may be temporary.

Serious or Rare Side Effects

  • Secondary malignancies: risk of developing new cancers after treatment.
  • Severe infections: due to profound immunosuppression.
  • Pulmonary toxicity: interstitial pneumonitis or fibrosis.
  • Renal impairment: decreased kidney function in susceptible patients.
  • Cardiotoxicity: rare cardiac dysfunction or arrhythmias.

Precautions & Warnings

Prior to initiating therapy, clinicians should assess patient-specific factors and monitor for potential complications.

  • Baseline blood counts: obtain complete blood count to evaluate marrow reserve.
  • Renal function: assess serum creatinine and adjust dosing if necessary.
  • Hepatic status: monitor liver enzymes for potential toxicity.
  • Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss contraception.
  • Concomitant myelosuppressive agents: use with caution to prevent excessive bone‑marrow suppression.
  • Store at ambient temperature: keep in original container, protect from moisture and light, and do not freeze.

Avoid Interactions

Melphalan may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • High‑dose cyclophosphamide: additive bone‑marrow toxicity.
  • Live vaccines: increased risk of infection due to immunosuppression.
  • Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely)

  • Allopurinol: may increase melphalan plasma levels.
  • Antiemetics (e.g., ondansetron): monitor for QT prolongation.
  • CYP450 inducers (e.g., rifampin): possible reduction in melphalan exposure.

Frequently Asked Questions

Melfalano Teva contains melphalan hydrochloride, an alkylating chemotherapy agent used to treat multiple myeloma, ovarian cancer, melanoma, neuroblastoma, and various other solid tumors as part of multi‑drug regimens.

Melphalan hydrochloride alkylates DNA by forming cross‑links at guanine bases, which blocks DNA replication and transcription. This interference triggers apoptosis in rapidly dividing cancer cells, reducing tumor growth.

The specific dose of Melfalano Teva is determined by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal function, and treatment protocol. Dosing regimens are individualized and not standardized.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Effective contraception should be used during treatment.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan is a nitrogen‑mustard alkylating agent with a broad spectrum of activity against both hematologic and solid tumors. Compared with agents like cyclophosphamide, melphalan often requires lower dosing frequencies but may have a higher risk of myelosuppression and secondary malignancies.

Store at ambient temperature: keep the product in its original packaging, protect from moisture and light, and do not freeze. Ensure the container is sealed and handle with aseptic technique when preparing for intravenous administration.

Melfalano Teva is given as an intravenous infusion. The preparation is diluted in an appropriate carrier solution and administered over a prescribed period under clinical supervision, typically in an oncology infusion center.

Serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, pulmonary toxicity, renal impairment, and rare cardiac events. Patients should be closely monitored for signs of infection, respiratory distress, and organ dysfunction.

Patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, those with severe bone‑marrow failure, uncontrolled infections, or significant organ dysfunction should not receive Melfalano Teva. Pregnant or breastfeeding individuals are also contraindicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Melphalan Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT